Narrative updates are currently in beta.

Back to narrative

Update shared on15 Aug 2025

Fair value Increased 13%
AnalystConsensusTarget's Fair Value
HK$35.90
4.2% overvalued intrinsic discount
15 Aug
HK$37.42
Loading
1Y
57.6%
7D
21.6%

The notable increase in China Literature’s analyst price target reflects substantial upgrades to both revenue growth and net profit margin forecasts, resulting in a new fair value estimate of HK$35.90.


What's in the News


  • Board meeting scheduled to consider interim results for the six months ending June 30, 2025, and potential interim dividend payment.
  • Commenced share repurchase program authorized to buy back up to 10% of issued share capital (102,208,922 shares), aiming to enhance net asset value and/or earnings per share.

Valuation Changes


Summary of Valuation Changes for China Literature

  • The Consensus Analyst Price Target has significantly risen from HK$31.90 to HK$35.90.
  • The Consensus Revenue Growth forecasts for China Literature has significantly risen from 4.2% per annum to 8.3% per annum.
  • The Net Profit Margin for China Literature has significantly risen from 14.77% to 18.94%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.